✦ LIBER ✦

Treatment of Hypertension in Obese Patients: Efficacy and Feasibility of Weight and Salt Reduction Programs

✍ Scribed by RISSANEN, A. ;PIETINEN, P. ;SILJAMÄKI-OJANSUU, U. ;PIIRAINEN, H. ;REISSEL, P.

Book ID: 114693984
Publisher: Wiley (Blackwell Publishing)
Year: 2009
Weight: 528 KB
Volume: 218
Category: Article
ISSN: 0001-6101
DOI: 10.1111/j.0954-6820.1985.tb08841.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weight reduction for treatment of obesit

Weight reduction for treatment of obesity-associated hypertension: Nuances and challenges

✍ Allyn L. Mark 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 134 KB

Efficacy and safety comparative evaluati

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

✍ G. Derosa; A. F. G. Cicero; G. Murdolo; M. N. Piccinni; E. Fogari; G. Bertone; L 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

The Efficacy and Safety of Valsartan in

The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients

✍ Kevin E. C. Meyers; Kenneth Lieberman; Susan Solar-Yohay; Guangyang Han; Victor 📂 Article 📅 2011 🏛 Le Jacq Communications, Inc. 🌐 English ⚖ 270 KB

Reduction of weight and left ventricular

Reduction of weight and left ventricular mass with serotonin uptake inhibition in obese patients with systemic hypertension

✍ Jens Jordan; Franz H. Messerli; Carl J. Lavie; Franz C. Aepfelbacher; Federico S 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Pritor in the treatment of patients with

Pritor in the treatment of patients with hypertension and obesity

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Effect of dexfenfluramine treatment on b

Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients

✍ J. Kolanowski; L. T. Younis; R. Vanbutsele; J. -M. Detry 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 839 KB

The effect of dexfenfluramine (dF) on body weight, blood pressure and noradrenergic activity were studied in 30 obese hypertensive patients randomly divided into two groups and treated for 3 months either with dF (30 mg daily; 16 subjects) or placebo (Pl; 14 subjects). 11 patients from the dF group